ArticleSN comprehensive clinical medicine2020
Analysis of COVID-19 Cases and Public Measures in China.
Article in SN comprehensive clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 23 citations in OpenAlex.
- Article
- Hyperuricemia and adverse outcomes in patients with cardiorenal syndrome: A nationwide prospective cohort study in China.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- Changes in diabetes care and management practices during the COVID-19 pandemic.Journal of public health (Oxford, England) · 2025Article
- Depression in pregnant non-diabetic women and women with gestational diabetes in Bangladesh-a comparative study based on multiple logistic regression.Diabetology international · 2025Article
- Marine natural products and human immunity: novel biomedical resources for anti-infection of SARS-CoV-2 and related cardiovascular disease.Natural products and bioprospecting · 2024Review
- Adopting sustainable innovations for remote access to TB and HIV care in South Africa.PLOS global public health · 2024Article
- History of traditional Mongolian medical education based onHealth science reports · 2023Article
- Emergency Protective Measures and Strategies of COVID-19: From Lifestyle to Traditional Chinese Medicine.Clinical complementary medicine and pharmacology · 2023Review
- A systematic review on post-discharge venous thromboembolism prophylaxis in patients with COVID-19.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2023Review
- The Efficacy and Safety of Shashen-Maidong Decoction Combined with Western Medicine in the Treatment of Omicron Infected Individuals Over 85 Years Old: A Retrospective Study.Infection and drug resistance · 2023Article
- Quarantine, physical distancing and social isolation measures in individuals potentially exposed to SARS-CoV-2 in community settings and health services: a scoping review.Nepal journal of epidemiology · 2022Article
- Occupational hazards in anaesthesiology during the COVID-19 pandemic.Anaesthesiology intensive therapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper briefly analyzes COVID-19 cases during Wuhan lockdown and travel restrictions on 23 January 2020 to 23 June 2020, which included total confirmed, in critical condition, deaths, recovered, and suspected cases in China. Results showed that there were 28,942 suspected cases on February 8, 2020, at the peak; then, it almost declined continually to only several cases. Total confirmed cases were more than 80,000 on March 1, 2020, but less than 84,000, and deaths were more than 3000 on March 4, 2020, but less than 4640, totally, thanks for the right public measures for COVID-19 in China, such as the Wuhan City lockdown and travel restrictions for isolation; positive screening and testing; and establishing a Huoshenshan hospital, a Leishenshan hospital, and a number of Fangcang shelter hospitals, traditional Chinese medicine and a combination of Chinese and western medicine, and the launch of the clinical trials of antiviral drugs (Lianhua Qingwen, remdesivir, and chloroquine). In addition, the iRT-ABCDEF program is very useful to control domestic, imported, and asymptomatic cases. Cases in critical condition decrease continually after the peak of 11,977 cases on February 18, 2020, and recovered cases increase continually to over 78,400 cases due to these right public measures and effective treatments. In recent months, there are only 2 deaths and only about ten cases in critical condition. All in all, these public measures in China are confirmed to be very effective and are worth conducting in countries worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.